Half of all radiotherapy treatment episodes in England in 2012 were delivered with palliative intent (65,580 episodes) [@b0005]. Palliative radiotherapy is widely used to relieve symptoms from either the primary tumour or sites of metastatic disease in advanced cancer. Clinical trials have demonstrated that hypofractionated treatment provides equivalent symptomatic benefit to longer courses, with limited toxicity [@b0010]. The decision to fractionate treatment, with increased acute toxicity and treatment burden, is sometimes made when it is considered necessary to relieve symptoms or with the aim of durable disease control, although the evidence base for this approach is limited. The balance between symptomatic benefit and the opportunity costs associated with excessive interventions must, therefore, be carefully considered and studied.

Many factors may influence the decision to offer and to fractionate palliative radiotherapy. These include the performance status of the patient, anatomical site of disease, primary diagnosis, co-morbidity, age, access to a clinical oncology opinion, travelling time to the treatment centre, clinician specific factors (including financial incentives) and the estimated life expectancy of the patient [@b0015]. However many of these factors are not prospectively recorded in national datasets.

Studies have shown that oncologists are poor at predicting survival of patients with advanced cancer with a tendency to be overly optimistic [@b0020; @b0025]. This may expose terminally ill patients to the burden of longer fractionated courses of radiotherapy [@b0025; @b0030]. Such overly aggressive cancer care at the end of life has a detrimental effect on quality of life and has previously been suggested as a quality of care issue [@b0035; @b0040]. Conversely, fear of over treatment amongst medical colleagues has also been cited as a possible factor reducing access to palliative radiotherapy [@b0045].

The palliative intent of treatment in patients with symptoms of advanced cancer means it is inevitable that early mortality due to disease progression will occur in some patients. The NHS policy document, 'Improving outcomes: A strategy for cancer', proposed mortality within 30-days of treatment (a commonly used metric in other health interventions) as a clinical indicator to assess the avoidance of harm in palliative radiotherapy [@b0050]. Early, US based, studies examining 30-day mortality (30DM) in palliative radiotherapy showed significant mortality in some groups [@b0055; @b0060], but no large population-based studies have been reported. These studies do not consider the relationship between fractionation and outcomes, focussing on access to treatment. Prognostic models for life expectancy amongst the general cancer population [@b0065; @b0070] and specifically death within 30 days of palliative radiotherapy [@b0075] have recently been published. However these are not used in routine clinical practise.

Alongside the need to ensure avoidable harm is minimised, there is a need for global healthcare systems to justify treatments in terms of value for money. Excessive fractionation may be considered in both these contexts (hypofractionation being increasingly advocated in the USA) [@b0080]. Measures which can aid the assessment of the appropriateness of treatment are, therefore, needed.

The use of 30DM as a clinical indicator for the avoidance of harm, through appropriate patient selection, in palliative radiotherapy has not previously been demonstrated. This study investigated the rate of 30DM following palliative radiotherapy in a single cancer centre serving a population of 2.8 million over a 7 year period and considered its value as a clinical indicator.

Methods {#s0010}
=======

All radiotherapy episodes delivered in a large UK cancer centre (Leeds Cancer Centre), between January 2004 and April 2011, were identified using the electronic patient record system (Patient Pathway Manager (PPM)). PPM collates and prospectively integrates electronic information on all cancer patients treated within the centre; patient (date of birth and sex) and treatment information (date of treatment, planned fractionation, dose, intent of treatment and site of treatment) were extracted for this analysis.

These data were then linked to the cancer registrations held by the National Cancer Registration Service (Northern and Yorkshire) and diagnostic, death and socioeconomic status (SES) information was extracted for all linked records. SES was categorised on the basis of rank quintile of deprivation score (Index of Multiple Deprivation (IMD), ONS 2010 version) [@b0085], for the Lower Super Output Area (population defined geographical region of approximately 1500 people [@b0090]) the patient lived in at diagnosis.

Leeds Cancer Centre (LCC) is a university affiliated centre serving a population of 2.8 million. The number of clinical oncologists increased from 18 to 30 during the study period. All oncologists are site specialised to a maximum of three primary diagnostic groups and are trained in the use of palliative radiotherapy. LCC is resourced through a national NHS tariff system where the reimbursement of the centre reflects the complexity of treatment planning and separately the number of fractions with complexity of treatment delivery. LCC were early adopters of the evidence supporting hypofractionation within palliative radiotherapy. Throughout the study period treatment has been delivered within well-defined clinical protocols e.g., palliative radiotherapy for uncomplicated bone metastases is delivered as a single fraction unless there is clear justification for a fractionated high dose approach. Departmental clinical protocols and a robust electronic patient record allow the study cohort to be defined.

Definition of palliative intent {#s0015}
-------------------------------

Treatment intent was identified as palliative by the treating clinician (centre policy) or if delivered in less than five fractions (exceptions to this were identified e.g., stereotactic body radiotherapy). The site treated was allocated as bone, brain, chest, soft tissue (e.g., treatment to the chest for oesophageal cancer), or unknown on the basis of the treatment site protocol (a free text field entered at the time of treatment), the diagnosis and intention of treatment.

In order to limit this investigation to adult palliative radiotherapy treatments, for solid organ tumours and to ensure data quality, a number of exclusions were made ([Fig. 1](#f0005){ref-type="fig"}). Radical treatments (24,516), episodes with incomplete data (540), treatments for benign diagnoses (37), non-melanomatous skin cancer (196) and haematological diagnoses (901) were excluded. Within the centre patients under the age of 25 are treated within the paediatric and young adolescent practice, 96 episodes delivered to this group were also excluded. Where multiple palliative treatments were delivered with the same start date, these were amalgamated into a single record (having been related to a single clinical decision). The fractionation allocated to this event was the largest of the concurrent treatments, this being the more significant clinical decision. 1534 episodes were amalgamated with another record in this way and considered as a single episode. Where overlapping treatment episodes were delivered with differing start dates it is not possible to know if these relate to a single clinical decision. For clarity these were considered separately.

The primary diagnosis was categorised into seven groups based on the most commonly occurring tumours. The major primary diagnoses were lung, breast, prostate, colorectal, bladder and oesophagus, with a separate category, 'other', consisting of all other cancer diagnoses and those patients with multiple, non-coincident diagnoses.

30-day mortality and survival {#s0020}
-----------------------------

The proportion dying within 30-days from treatment start was assessed for all treatments within the cohort and by numbered courses in relation to fractionation delivered, primary diagnosis and site treated. The Chi-squared test was used to assess the impact of various factors upon early mortality. A logistic regression model was used to investigate the factors associated with death within 30-days of the start of palliative radiotherapy. The dependent variable, death within 30-days, was considered as a binary outcome. Covariates (explanatory variables) in the model included, age at start of radiotherapy, sex, socioeconomic status, site of the primary tumour, site of irradiation, fractionation pattern and year of treatment.

Survival was calculated from the start of each palliative radiotherapy episode to date of death or when censored (30th April 2012). The start date of treatment was used as it is closer to the clinical decision to treat than the end of treatment and provides a uniform time point across all fractionation regimens, aligning with NCEPOD systemic therapy methodology [@b0095]. As individuals who underwent multiple sequential treatment episodes had, by definition, to survive all previous treatments and to ensure people could not enter survival analyses twice the univariate logistic regression model and illustrative Kaplan--Meier survival curves were produced based on first and second treatment episodes separately. Multivariate analysis considered only the first treatment episode. Univariate logistic regression was also carried out for all treatment episodes combined, this overall analysis is likely to be a closer reflection of the measure as applied in future, on a population level; including every clinical decision within the cohort. Statistical analyses were carried out using STATA IC 13.

Results {#s0025}
=======

42,792 radiotherapy treatment episodes were identified. Within this a total of 18,275 palliative treatment episodes, delivered to 12,240 individuals, were identified. Of these, 3303 (18.1%) episodes in 1144 individuals were excluded ([Fig. 1](#f0005){ref-type="fig"}), leaving a study population of 14,972 episodes delivered to 11,096 people.

[Table 1](#t0005){ref-type="table"} shows the characteristics of the population undergoing palliative radiotherapy. The median age at treatment was 70 years (range 25--101). The majority of palliative radiotherapy episodes (55.3%) were delivered to men. Lung (25.3%), breast (14.7%), prostate (14.5%) and colorectal (5.2%) cancers were the most frequently treated primary diagnoses. The commonest irradiated site was bone with 4407 individuals receiving 6334 (42.3%) courses of treatment to bone alone or bone combined with another site. Soft tissue (3691 (24.7%)) and chest (3628 (24.2%)) were the next most commonly irradiated sites.

61.9% of patients received treatment consisting of four or less radiotherapy fractions (50.5% single and 11.4% 2--4 fractions). 23.7% of patients received five fractions, 2.2% received 6--9 treatments and 12.3% 10 or more fractions.

30-day mortality and survival {#s0030}
-----------------------------

Overall, 1846 (12.3%) individuals died within 30 days of the initiation of a course of palliative radiotherapy. Variations of 30DM in relation to the characteristics of the population and treatment episodes are shown in [Table 2](#t0010){ref-type="table"}. The median survival time for the whole cohort was 169 days (Inter-Quartile Range (IQR) 67--436 days). Significant variation in survival patterns was seen however in relation to both the primary diagnosis and fractionation pattern ([Fig. 2](#f0010){ref-type="fig"} and [Supplementary Fig. 1S](#s0060){ref-type="sec"} respectively).

[Table 3](#t0015){ref-type="table"}, [Fig. 3](#f0015){ref-type="fig"} and [Supplementary Fig. 2S](#s0060){ref-type="sec"} show patterns of radiotherapy fractionation, 30DM and survival following treatment to bone. Overall 30DM was 14.1%; there was significant variation in relation to primary diagnosis and fractionation pattern (*p* \< 0.001).

Palliative radiotherapy to the chest for lung cancer accounted for 2356 (15.7%) treatments and was associated with 30DM of 14.0%, this was significantly related to fractionation, *p* \< 0.01. Median treatment time for all palliative treatments for lung cancer to the chest was 8 days (IQR 1--12). The most commonly used fractionation schemes reflect local protocols: 1 (32%), 2 (30%), 5 (13.72%), 12 (8.64%) and 13 (7.70%).

915 (5.65%) episodes of palliative radiotherapy to the brain were delivered within the cohort, of these 68 were accompanied by treatment to a second site. The two most frequently treated metastatic diagnoses were breast and lung cancer (205 (22.4%) and 192 (21.0%) respectively of total) with primary brain tumours accounting for 160 (17.5%) treatments. Overall 30DM was 11.2%, with breast, lung, and primary brain cancers having 30DM of 11.2%, 15.1%, and 5.6% respectively ([Supplementary Material, Fig. 3S](#s0060){ref-type="sec"}).

Significant variation in 30DM was apparent in relation to sex, age, primary diagnosis, treatment site, IMD and fractionation schedule adopted. Age and IMD did not retain their significance in multivariate analysis ([Supplementary Material Table 3S](#s0060){ref-type="sec"}). Socioeconomic status (SES) (as measured by IMD) has been shown to impact significantly upon cancer outcomes [@b0100], the reasons for this are not entirely clear however SES may be a surrogate for co-morbidity. Females had a 16% reduction in the odds of death within 30 days compared to males (Odds Ratio (OR) 0.84, 95% Confidence Interval (CI) 0.74--0.96, *p* = 0.010) even after adjustment for other case mix factors. A statistically significant relationship between increasing fractionation schedules and reduction in the odds of death within 30-days was observed. Those receiving 10 or more fractions were 90% less likely to die within 30-days of the start of radiotherapy compared to those receiving just one fraction (OR 0.10, 95% CI 0.08--0.14, *p* \< 0.001). Of note there was no significant variation in early mortality with time (*p* = 0.391).

Discussion {#s0035}
==========

This is the first large, population-based study investigating 30DM following palliative radiotherapy in a single centre that is the sole provider of radiotherapy to a large population. An overall 30 DM rate of 12.3% was observed, aligning well with other recently published data for first palliative radiotherapy treatments [@b0065].

In this cohort of patients the site most frequently irradiated was bone. Overall 30DM for these treatments was 14.1%. The literature suggests the median time to treatment benefit following palliative radiotherapy to bone is 14 days, with response rates of between 50% and 70% [@b0105; @b0110]. The risk of pathological fracture and the need for re-treatment, following single fraction radiotherapy to bone metastases may contribute to the use of fractionated radiotherapy in this setting. Median time to re-treatment has been reported to be 25 weeks after a single fraction [@b0115]. International evidence strongly favours the use of single fraction treatments in uncomplicated bone metastases [@b0105; @b0120]. Our early mortality outcomes suggest this evidence base has been appropriately applied in this study population. Fractionated courses of radiotherapy to bone were associated with significantly lower 30DM.

Palliative radiotherapy to the brain had a 30DM of 11.6% overall. Despite the selective use (⩽40 episodes, ⩽10 deaths) of palliative radiotherapy to the brain for some poor prognosis groups within our cohort, early mortality remains high (e.g., melanoma (21.9%), unknown primary (24.0%) (data not shown)). The benefit of whole brain radiotherapy for metastases, as compared to supportive care alone, has not been assessed in randomised controlled trials in the CT era [@b0155], the final outcome of the QUARTZ trial is awaited [@b0130].

30DM for lung cancer patients treated with palliative radiotherapy was 17.3% (similar to equivalent figures published in the USA [@b0060]). Those receiving treatment to the primary had a 30DM of 14.1%, which was significantly related to fractionation (*p* \< 0.01). 30DM following 1--2 fraction treatments (22.5%) was markedly higher than that following ten or more fraction treatments (2.5%). Median time to symptom improvement following thoracic radiotherapy for NSCLC is approximately 1--2 months [@b0135; @b0140]. Excessive fractionation in poor performance status, lung cancer patients cannot be justified given well documented evidence supporting the use of hypofractionation for equivalent symptom control in this group [@b0140].

30DM varies significantly with primary diagnosis, the site being irradiated, patient sex and the fractionation pattern chosen. Greater use of more fractionated treatments, increased treatment burden and potentially higher acute toxicity are harder to justify in diagnoses with poor prognosis. There are a limited number of palliative settings in which more fractionated treatments are known to improve survival. We believe that the variation demonstrated with fractionation reflects appropriate clinical decision making, encompassing predicted prognosis, in the context of clinical protocols which in themselves reflect the underpinning evidence. This supports the use of 30DM as a measure of clinical decision making in palliative radiotherapy.

Survival with symptomatic disease has increased with increasing systemic therapy options. It is unclear however if the point within the disease trajectory at which palliative radiotherapy is delivered has changed. Lack of variation in early mortality with time demonstrated here suggests that clinical decision making near the end of life is stable.

We have shown that it is possible to audit 30DM, in a large unselected population. The size of this dataset allows analysis of subgroups by diagnosis and site treated whilst also maintaining statistical power. In addition, the single centre from which the data were derived was an early adopter of the evidence supporting the hypofractionation of palliative radiotherapy (increasingly advocated globally, including in the USA) [@b0080] and patients were treated within site specific teams, to consistent clinical protocols (adopted at the start of the study period). This study has some limitations:•It reflects practice within a single, large NHS centre.•Planned fractionation was used for all analyses as it most closely reflects the clinical decision to treat, however it may not always be the fractionation actually delivered. Delivered fractionation was not available across the whole cohort. If, in the future, such data can be captured the strength of any analyses undertaken would be increased.•Data within the electronic patient record reflect routine clinical practice and were not prospectively coded for research purposes. The allocation of target tissue and intent of treatment was based upon fixed algorithms. Manual review, by investigating clinicians, of a sample of cases, revealed high levels of concordance of these fields (results not shown) indicating allocation algorithms were robust. A database with defined coding rules, to include not only anatomical site but also target tissue and re-irradiation would also be beneficial. Whilst the current national Radiotherapy Dataset (RTDS) includes coding of anatomical site these data are inadequate due to variations in the application of the coding rules.

It has previously been shown that chemotherapy prescribing behaviour among medical oncologists can be influenced by feeding back early mortality outcomes [@b0025; @b0035; @b0145; @b0150]. Oncologists prescribing palliative radiotherapy often do not have an opportunity to follow up individual patients, so providing feedback in the form of 30DM outcomes for palliative radiotherapy to clinicians or teams may be beneficial. A future analysis of 30DM within the RTDS would also allow comparisons between centres and may be of value in clinical policy setting and commissioning. Outlying results would merit further study to determine the underlying causes and whether this reflected appropriate variation in practise, refinement of this assessment process is anticipated over time.

NCEPOD [@b0095] in surgery and chemotherapy has led to the routine practise of a retrospective review of all deaths within 30 days. We would recommend an analogous approach, however for single fraction palliative radiotherapy this may be impractical due to the high numbers (16.7%). In those receiving a single fraction the burden of treatment is minimal but the potential for benefit within 30 days still significant. An earlier time point, possibly mortality within 14 days (suggested from the survival curves in [Fig. 2S (Supplementary Material)](#s0060){ref-type="sec"}), may be more pragmatic for a retrospective case note review. The variation in treatment burden and incremental benefits with fractionation must be borne in mind when considering 30DM outcomes. Whilst many factors may contribute to this decision making process clinicians must be vigilant to the risk of early mortality when deciding to fractionate palliative treatments. Practise will vary, with evidence demonstrating the impact of financial incentives upon the fractionation of radiotherapy [@b0015]. These may be in direct conflict with the need to reduce treatment burden for terminally ill patients. As the availability of highly conformal radiotherapy increases, the use of high dose, hypofractionated palliative radiotherapy will increase. The benefits in terms of reduced treatment burden (both from reduced normal tissue toxicity and decreased visits) are clear, however the cost implications for the department are significant and careful case selection will remain important.

30DM has been recommended as a clinical indicator of the avoidance of harm in palliative radiotherapy. It is suited to this in a number of ways: It is objective, clinically relevant, measurable in a timely manner at a population level and may encourage improvements both in the avoidance of harm and cost-effectiveness of palliative radiotherapy services. However, there are limitations to the use of 30DM. It is a single outcome measure; patient reported outcomes of symptomatic benefit and re-irradiation rates would be valuable as complimentary measures to provide reassurance that patients were not being undertreated. More fractionated palliative radiotherapy would be expected to have a lower 30DM but by contrast any move to reduce 30DM without reference to fractionation patterns may have a detrimental impact on access to appropriate hypofractionated palliative radiotherapy. There will be considerable debate about what constitutes optimal 30DM. Future work, involving more in depth analysis of a smaller population, allowing assessment of performance status, patient preferences and outcomes would be valuable. This, alongside an assessment of the impact of implementing 30DM, would allow validation of the measure as a clinical indicator.

This is the first large-scale description of 30-day mortality for unselected adult palliative radiotherapy treatments. Significant variation is demonstrated with diagnosis, sex, treatment site and, importantly, fractionation. In this setting, a measure which can help to assess the appropriateness of treatment and avoidance of harm (as demanded by providers of health care) [@b0050] is required. 30DM has a significant value as a retrospective measure of departmental palliative radiotherapy outcomes when considered alongside fractionation patterns. Clearly separated 30DM outcomes by fractionation would provide reassurance that clinical decision making was appropriate. It does not attempt to assess or guide individual clinical decisions. The observed differences in early mortality by fractionation support further study in other centres and health care systems. Our results suggest it is of value in assessing department wide clinical decision making in palliative radiotherapy providing parity with the early metrics used in other healthcare interventions.
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![Consort diagram demonstrating exclusions from the study population.](gr1){#f0005}

![Survival and 30 DM following the start of palliative radiotherapy in relation to primary diagnosis.](gr2){#f0010}

![Survival and 30 DM following palliative radiotherapy to bone by fractionation pattern (6--9 fraction treatments are not included here due to small numbers (*n* = 6)).](gr3){#f0015}

###### 

Characteristics of the study population. The majority of the population underwent a single episode of palliative radiotherapy, but 2625 individuals underwent two or more episodes (3876 episodes). Only 772 patients received three or more courses. Due to the limited size of this latter population information is presented by first episode, second episode and overall within the cohort.

  Characteristic                           Episode number   All episodes                                  
  ---------------------------------------- ---------------- -------------- ------ ------ -------- ------- ------
  Age at initial palliative radiotherapy   ⩽50              847            7.6    275    10.5     1273    8.5
  51--60                                   1766             15.9           490    18.7   2529     17.0    
  61--70                                   3051             27.5           769    29.3   4197     28.2    
  71--80                                   3439             31.0           736    28.0   4503     30.2    
  \>80                                     1993             18.0           355    13.5   2470     16.6    
                                                                                                          
  Sex                                      Male             6053           54.6   1478   56.3     8244    55.3
  Female                                   5042             45.4           1147   43.7   6727     45.1    
                                                                                                          
  IMD category                             Most deprived    2663           24.0   574    21.9     3501    23.5
  2                                        2194             19.8           515    19.6   2955     19.8    
  3                                        1849             16.7           425    16.2   2466     16.6    
  4                                        2318             20.9           565    21.5   3157     21.2    
  Most affluent                            1841             16.6           504    19.2   2606     17.5    
  Unknown                                  231              2.1            42     1.6    287      1.9     
                                                                                                          
  Primary cancer diagnosis                 Other            3997           36.0   852    32.5     5185    34.8
  Lung                                     3070             27.7           548    20.9   3770     25.3    
  Breast                                   1378             12.4           478    18.2   2186     14.7    
  Prostate                                 1232             11.1           533    20.3   2154     14.5    
  Colorectal                               631              5.7            120    4.6    778      5.2     
  Oesophagus                               414              3.7            51     1.9    468      3.1     
  Bladder                                  374              3.4            44     1.7    431      2.9     
                                                                                                          
  Site of irradiation                      Multiple         892            8.0    285    10.9     1339    9.0
  Bone                                     3321             29.9           1294   49.3   5379     36.1    
  Brain                                    704              6.3            106    4.0    846      5.7     
  Chest                                    3224             29.1           337    12.8   3628     24.3    
  Soft tissue                              2901             26.1           576    21.9   3691     24.8    
  Unknown                                  54               0.5            27     1.0    89       0.6     
                                                                                                          
  Fractionation                            1                4813           43.4   1759   67.0     7558    50.5
  2--4                                     1503             13.5           157    6.0    1706     11.4    
  5                                        1763             15.9           585    22.3   3547     23.7    
  6--9                                     299              2.7            24     0.9    325      2.2     
  ⩾10                                      1718             15.5           100    3.8    1836     12.3    
                                                                                                          
  Year of treatment                        2004             1636           14.7   272    10.4     1982    13.2
  2005                                     1489             13.4           386    14.7   2071     13.8    
  2006                                     1430             12.9           362    13.8   1990     13.3    
  2007                                     1345             12.1           340    13.0   1847     12.3    
  2008                                     1535             13.8           330    12.6   2024     13.5    
  2009                                     1498             13.5           399    15.2   2086     13.9    
  2010                                     1666             15.0           398    15.2   2274     15.2    
  2011                                     497              4.5            138    5.3    698      4.7     
                                                                                                          
  Total                                    11,096           74.1           2625   17.5   14,972   100.0   

###### 

30-day mortality in relation to the characteristics of the population (as in [Table 1](#t0005){ref-type="table"}, episodes are considered as first, second and overall within the cohort).

  Characteristic                           Episode 1            Episode 2   All episodes                                                                              
  ---------------------------------------- -------------------- ----------- -------------- ------- --------- ------- ------- ------- --------- ------ ------- ------- ---------
  Age at initial palliative radiotherapy   ⩽50                  847         85             10.04   0.110     275     40      14.55   0.084     1273   141     11.08   0.010
  51--60                                   1766                 212         12.00          490     70        14.29   2529    327     12.93                            
  61--70                                   3051                 382         12.52          769     116       15.08   4197    547     13.03                            
  71--80                                   3439                 438         12.74          736     92        12.50   4503    573     12.72                            
  \>80                                     1993                 219         10.99          355     33        9.30    2470    258     10.45                            
                                                                                                                                                                      
  Sex                                      Male                 6053        795            13.13   \<0.001   1478    215     14.55   0.045     8244   1110    13.46   \<0.001
  Female                                   5042                 541         10.73          1147    136       11.86   6727    736     10.94                            
                                                                                                                                                                      
  IMD category                             Most deprived        2663        332            12.47   0.148     574     87      15.16   0.079     3501   459     13.11   0.025
  4                                        2194                 283         12.90          515     82        15.92   2955    390     13.20                            
  3                                        1849                 233         12.60          425     53        12.47   2466    313     12.69                            
  2                                        2318                 267         11.52          565     65        11.50   3157    367     11.62                            
  Most affluent                            1841                 191         10.37          504     56        11.11   2606    278     10.67                            
  Unknown                                  231                  30          12.99          42      8         19.05   287     39      13.59                            
                                                                                                                                                                      
  Site of primary                          Multiple and Other   3997        479            11.98   \<0.001   852     108     12.68   \<0.001   4542   643     14.16   \<0.001
  Lung                                     3070                 489         15.93          548     133       24.27   3770    652     17.29                            
  Breast                                   1378                 92          6.68           478     32        6.69    2186    152     6.95                             
  Prostate                                 1232                 89          7.22           533     41        7.69    2154    161     7.47                             
  Colorectal                               631                  72          11.41          120     22        18.33   778     99      12.72                            
  Oesophagus                               414                  50          12.08          50      6         12.00   468     59      12.61                            
  Bladder                                  374                  65          17.38          44      9         20.45   431     80      18.56                            
                                                                                                                                                                      
  Site of irradiation                      Multiple             892         173            19.39   \<0.001   285     46      16.14   \<0.001   1339   242     18.07   \<0.001
  Bone                                     3321                 460         13.85          1294    163       12.60   5379    715     13.29                            
  Brain                                    704                  71          10.09          106     19        17.92   846     95      11.23                            
  Chest                                    3224                 381         11.82          337     73        21.66   3628    467     12.87                            
  Soft tissue                              2901                 241         8.31           576     46        7.99    3691    313     8.48                             
  Unknown                                  54                   10          18.52          27      4         14.81   89      14      15.73                            
                                                                                                                                                                      
  Fraction group                           1                    4813        873            18.14   \<0.001   1759    259     14.72   \<0.001   7558   1265    16.74   \<0.001
  2--4                                     1503                 166         11.04          157     31        19.75   1706    203     11.90                            
  5                                        1763                 235         13.33          585     54        9.23    3547    309     8.71                             
  6--9                                     299                  16          5.35           24      2         8.33    325     18      5.54                             
  ⩾10                                      1718                 46          2.68           100     5         5.00    1836    51      2.78                             
                                                                                                                                                                      
  Year of treatment                        2004                 1636        187            11.43   0.745     272     35      12.87   0.865     1982   232     11.71   0.719
  2005                                     1489                 197         13.23          386     51        13.21   2071    278     13.42                            
  2006                                     1430                 178         12.45          362     56        15.47   1990    258     12.96                            
  2007                                     1345                 161         11.97          340     40        11.76   1847    224     12.13                            
  2008                                     1535                 181         11.79          330     42        12.73   2024    240     11.86                            
  2009                                     1498                 186         12.42          399     50        12.53   2086    257     12.32                            
  2010                                     1666                 186         11.16          398     59        14.82   2274    273     12.01                            
  2011                                     497                  60          12.07          138     16        11.59   698     84      12.03                            
                                                                                                                                                                      
  Total                                    11,096               1336        12.04                  2625      351     13.37           14,972    1846   12.33           

###### 

30-day mortality following palliative radiotherapy to bone.

  Characteristic          Episode 1   Episode 2   All episodes                                             
  ----------------------- ----------- ----------- -------------- ------ ------ ------ ------ ------ ------ ------
  Fraction group          1           3292        558            17.0   1005   123    12.2   4863   744    15.3
  2--4                    103         15          14.6           26     1      3.8    145    19     13.1   
  5                       825         95          11.5           198    22     11.1   1117   125    11.2   
  6--9                    6           0           0.0            2      0      0.0    9      0      0.0    
  ⩾10                     181         3           1.7            12     0      0.0    200    6      3.0    
                                                                                                           
  Primary diagnosis       Breast      821         62             7.6    284    13     4.6    1293   90     7.0
  Colorectal              238         36          15.1           40     8      20.0   285    46     16.1   
  Lung                    784         197         25.1           153    33     21.6   979    237    24.2   
  Prostate                966         64          6.6            419    39     9.3    1664   121    7.3    
  Renal                   196         25          12.8           51     7      13.7   287    40     13.9   
                                                                                                           
  Site of irradiation     Bone        3734        532            14.2   1066   123    11.5   5379   715    13.3
  Multiple bony sites     538         113         21.0           143    18     12.6   779    144    18.5   
  Bone and another site   135         29          21.5           34     5      14.7   176    35     19.9   
                                                                                                           
  Total                   4407        674         15.3           1243   146    11.7   6334   894    14.1   

[^1]: Joint last authors.
